BioCentury This Week

Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns

16 Jul 2024

Contributed by Lukas

Buysiders are upbeat headed into the back half of the year, but uncertainty over the Federal Reserve’s timing on interest rate cuts is keeping that ...

Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure

09 Jul 2024

Contributed by Lukas

The U.K.’s life sciences ecosystem boasts “palpable energy at the very innovation end of the spectrum in biotech, with a lot of really quality sci...

Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner

02 Jul 2024

Contributed by Lukas

The impact on FDA and the biopharma industry of the Supreme Court’s move to overturn the legal doctrine that courts defer to federal agencies’ int...

Ep. 239 - Rare Disease Spotlight: MPS & DMD

25 Jun 2024

Contributed by Lukas

A biomarker breakthrough could shave years off the development of therapies for a group of devastating, progressive ultrarare diseases. On the latest ...

Ep. 238 - Biosecure Act: The Impact & What's Ahead

20 Jun 2024

Contributed by Lukas

After whisking through Washington for the first half of the year, raising alarms, mutating and causing confusion, the Biosecure Act is now on pause. O...

Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS

18 Jun 2024

Contributed by Lukas

The avian flu outbreak is a fire drill that is showing how poorly the U.S. is prepared for the next pandemic. On the latest BioCentury This Week podca...

Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

14 Jun 2024

Contributed by Lukas

BIO’s annual meeting took place amid heightened industry concerns regarding the Biosecure Act, which took yet another unexpected turn this week. On ...

Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

10 Jun 2024

Contributed by Lukas

A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. ...

Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update

03 Jun 2024

Contributed by Lukas

Four takeouts with upfront payments north of $1 billion to close out May mark the latest run of VC exits from biotech M&A and help expand the pipe...

Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A

28 May 2024

Contributed by Lukas

A theme among late-breaker presentations at this year’s American Society of Clinical Oncology meeting is the push by companies to move targeted ther...

Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data

20 May 2024

Contributed by Lukas

New BIO CEO John Crowley is reorganizing BIO in a bid to reshape how the organization communicates and enhance its focus on patients. BioCentury’s e...

Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more

16 May 2024

Contributed by Lukas

“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the...

Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note

14 May 2024

Contributed by Lukas

Lawmakers’ changes to the Biosecure Act create breathing room for U.S. biopharma companies to move on from Chinese CDMOs, Washington Editor Steve Us...

Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise

09 May 2024

Contributed by Lukas

It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular ...

Ep. 230 - Bio€quity Europe 2024 Preview

09 May 2024

Contributed by Lukas

Next week's Bio€quity Europe conference in San Sebastián will focus on how European biotechs can rise above the noise to attract investors, pa...

Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure

07 May 2024

Contributed by Lukas

One of the big themes of this week’s ASGCT meeting will be CAR T cells in cancer and beyond. On the latest BioCentury This Week podcast, BioCentury’...

Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera

30 Apr 2024

Contributed by Lukas

Led by CBER Director Peter Marks, FDA is moving forward with policies that aim to improve access to gene therapies for patients with rare diseases. On...

Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss

22 Apr 2024

Contributed by Lukas

A “drive-by analysis of accelerated approval is intellectual malpractice,” argues Washington Editor Steve Usdin on the latest BioCentury This Week...

Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves

16 Apr 2024

Contributed by Lukas

Vertex Pharmaceuticals' acquisition of Alpine Immune Sciences will bolster a growing kidney disease franchise that could help diversify Vertex’...

Ep. 225 - 2Q Markets Preview & AACR Takeaways

08 Apr 2024

Contributed by Lukas

M&A has been driving a recovery for biotech, with $62 billion in takeouts in the past six months restocking specialist investors’ coffers for th...

Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

02 Apr 2024

Contributed by Lukas

Upcoming catalysts could drive value creation at NASDAQ’s newest biotech, Boundless Bio, after it stumbled in its trading debut last week. On the la...

Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

26 Mar 2024

Contributed by Lukas

Bills seeking to rein in Chinese CDMOs and genomics companies will deal a massive blow to biotech companies, if passed in their current form, accordin...

Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts

18 Mar 2024

Contributed by Lukas

Putting patients at center stage is at the core of John Crowley’s vision for BIO as he begins his tenure leading the biotech trade group. On the lat...

Ep. 221 - China Biocontroversy, Plus: Diversity Matters

12 Mar 2024

Contributed by Lukas

A congressional committee meeting last week on biotech and national security provided a glimmer of hope that lawmakers could be persuaded to consider ...

Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight

05 Mar 2024

Contributed by Lukas

The $3 billion raised by biotechs in a series of follow-ons and PIPEs last week marked another strong showing for a sector seeking to outrun the bear ...

Ep. 219 - East-West Summit Preview

28 Feb 2024

Contributed by Lukas

Asia’s emerging “Arc of Innovation” spans from China, Japan and South Korea through the turf-neutral gateway of Singapore and west to India, wit...

Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases

27 Feb 2024

Contributed by Lukas

 Arch Venture Partners’ Bob Nelsen is excited about AI’s potential in biotech and convinced the U.S. healthcare system could do a far better job ...

Ep. 217 - Safer CAR Ts & World’s First TIL Therapy

21 Feb 2024

Contributed by Lukas

Off switches and non-viral delivery technologies may be the solution to CAR T therapies’ most recent safety problem. On the latest BioCentury This W...

Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond

16 Feb 2024

Contributed by Lukas

Anti-China biotech bills are raising alarms at U.S. biotechs, with CEOs worried they could lose access to CDMOs WuXi AppTec and WuXi Biologics, and th...

Ep. 215 - ADCs, Psychedelics & IPOs

13 Feb 2024

Contributed by Lukas

Innate immunity is getting another shot at cancer through antibody-drug conjugates, with immunostimulatory antibody-drug conjugates moving from concep...

Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech

06 Feb 2024

Contributed by Lukas

As it approaches a steep patent cliff, Bristol Myers is charting its course to bridge a transition period and return to growth. On the latest BioCentu...

Ep. 213 - Biotech IPOs & IL-18 Momentum

30 Jan 2024

Contributed by Lukas

NASDAQ’s first biotech public listings of 2024 provided hopeful signs for a rebound in the biotech IPO market. On the latest BioCentury This Week po...

Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact

23 Jan 2024

Contributed by Lukas

Biotech investors are looking to catalysts that can create, or dramatically expand, commercial markets as they look ahead to a long-awaited recovery f...

Ep. 211 - 2024 Markets Preview, Woodcock's Legacy

17 Jan 2024

Contributed by Lukas

Investors and bankers are as upbeat about biotech’s prospects heading into 2024 as they have been since 2020, but maintaining the momentum that bega...

Ep. 210 - J.P. Morgan Healthcare Conference Wrap

13 Jan 2024

Contributed by Lukas

Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of ...

Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024

05 Jan 2024

Contributed by Lukas

A flurry of large acquisitions to close out 2023 is likely to carry into the New Year as pharmas continue to show appetite for late-stage assets. On t...

Ep. 208 - XBI Rally, ASH Highlights & '24 Picks

19 Dec 2023

Contributed by Lukas

Signals from the Fed that rate cuts are on the way rallied biotech indexes last week, but is the uptick more than a blip? On the latest BioCentury Thi...

Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in

12 Dec 2023

Contributed by Lukas

FDA’s decision to approve two gene therapies for sickle cell diseases could be transformative for patients, but both multimillion-dollar drugs will ...

Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T

05 Dec 2023

Contributed by Lukas

Biopharma’s latest pair of multibillion-dollar takeouts come in two of industry’s hottest areas: ADCs and obesity. On the latest BioCentury This W...

Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech

28 Nov 2023

Contributed by Lukas

Radiopharmaceuticals have experienced a resurgence over the past decade, with a series of approvals, billion-dollar deals and growing sales. On the la...

Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans

20 Nov 2023

Contributed by Lukas

The world’s first approval of a CRISPR-based gene editing therapy, granted by the U.K.’s MHRA, was a milestone for the technology that was just di...

Ep. 203 - POC for Verve? Plus: IRA & East-West Deals

14 Nov 2023

Contributed by Lukas

Verve achieved the first proof of concept for an in vivo base editing therapy, but investor concerns weighed on the company’s stock, clouding the re...

Ep. 202 - A DMD Decision & Endpoint Innovation

07 Nov 2023

Contributed by Lukas

The controversy around Sarepta continues as the company’s executives were confident last week that the data from the Phase III EMBARK trial of Duche...

Ep. 201 - ESMO, NIH & IRA

30 Oct 2023

Contributed by Lukas

The European Society for Medical Oncology (ESMO) had everything from practice changing Phase III data readouts to new solid tumor targets. On the late...

Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors

24 Oct 2023

Contributed by Lukas

Daiichi Sankyo has drawn more value from its antibody-drug conjugate pipeline via a $4 billion deal with Merck & Co. On the latest BioCentury This...

Ep. 199 - China Summit Preview

20 Oct 2023

Contributed by Lukas

BayHelix’s Guo-Liang Yu and McKinsey’s Josie Zhou join the BioCentury This Week podcast to discuss cross-border innovation and deal flow in the bi...

Ep. 198 - Novartis Finds Focus & EU Pharma Law

16 Oct 2023

Contributed by Lukas

Now that Vas Narasimhan has finished the major dismantling of Novartis, he’s turning his attention to fixing R&D. On the latest BioCentury This ...

Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview

09 Oct 2023

Contributed by Lukas

BMS’s acquisition of Mirati for up to $5.8 billion not only gives the big pharma a potential best-in-class KRAS inhibitor in a field that appears to...

Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi

03 Oct 2023

Contributed by Lukas

Biopharma companies are moving quickly to figure out how to optimize CAR T cell therapies for autoimmune diseases now that it’s becoming clear the m...

Ep. 195 - East-West Summit Preview

25 Sep 2023

Contributed by Lukas

BayHelix’s Guo-Liang Yu and McKinsey’s Olivier Leclerc join the BioCentury This Week podcast to discuss cross-border innovation and deal flow in t...

Ep. 194 - IPO Outlook & IRA Lawsuits

19 Sep 2023

Contributed by Lukas

That a broad swath of new money flowed into last week’s IPOs by RayzeBio and Neumora is a good sign for biotech and a departure from deals done last...

Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC

12 Sep 2023

Contributed by Lukas

Constructing deal terms to take advantage of both the translational research benefits in China and the market opportunity in the U.S. is slowly emergi...

Ep. 192 - Tier-jumpers: a Back to School Overview

05 Sep 2023

Contributed by Lukas

What are the criteria that enable companies to achieve the kind of success that leads to a jump in market cap tier? On the latest BioCentury This Week...

Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits

22 Aug 2023

Contributed by Lukas

Circular RNA’s durability could convey efficacy and manufacturing advantages over therapies based on linear mRNA. On the latest BioCentury This Week...

Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial

14 Aug 2023

Contributed by Lukas

There’s a tectonic shift happening in obesity research and drug development, BioCentury Editor in Chief Simone Fishburn said on the latest BioCentur...

Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital

07 Aug 2023

Contributed by Lukas

A complete response letter from FDA in major depressive disorder could severely dent the commercial prospects for Zurzuvae zuranolone even as the drug...

Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations

31 Jul 2023

Contributed by Lukas

An analysis of pharma deal trends over the past year shows a focus on first-in-class assets with autoimmune diseases being a major focus of interest. ...

Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC

24 Jul 2023

Contributed by Lukas

A hypertension deal with Roche will help Alnylam execute on its growth strategy of moving into more prevalent diseases. On the latest BioCentury This ...

Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis

17 Jul 2023

Contributed by Lukas

With investors seeing the worst days fading into the rearview mirror, the sector has begun to chart a path out of the biotech bear market. On the late...

Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval

11 Jul 2023

Contributed by Lukas

Full approval of Leqembi lecanemab-irmb will unlock reimbursement and energize Alzheimer’s R&D, but the launch will be slow, said BioCentury Was...

Ep. 184 - Califf's FDA reforms & Polaris' Schulman

26 Jun 2023

Contributed by Lukas

FDA Commissioner Rob Califf’s biggest legacy could be his reform of FDA’s advisory committee process. But what is uncertain is whether his review ...

Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back

19 Jun 2023

Contributed by Lukas

Emer Cooke may have already cemented her legacy as executive director of EMA through her leadership of the European regulator during the COVID-19 cris...

Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO

13 Jun 2023

Contributed by Lukas

A lawsuit over the Inflation Reduction Act by Merck & Co. suit signals to Republicans that the pharma has no compunctions about attacking Democrat...

Ep. 181 - Highlights from ASCO

05 Jun 2023

Contributed by Lukas

ASCO’s kickoff included blunt comments from two CEOs who said the IRA is causing their companies to delay launches of cancer drugs for smaller indic...

Ep. 180 - ASCO, Neuropsych & the IRA

30 May 2023

Contributed by Lukas

Two Phase I checkpoint inhibitor readouts due at ASCO 2023 are bringing excitement back to immuno-oncology, said BioCentury’s Lauren Martz on the la...

Ep. 179 - DMD Gene Therapies, CBER & NIH

23 May 2023

Contributed by Lukas

If FDA approves Sarepta's gene therapy for Duchenne muscular dystrophy, patients will soon face the difficult choice between taking this treatmen...

Ep. 178 - Live from Bio€quity, Part 2

16 May 2023

Contributed by Lukas

As biotechs continue to find their footing in the new normal of capital scarcity, the industry is beginning to see “green shoots” in M&A activ...

Ep. 177 - Live from Bio€quity, Part 1

15 May 2023

Contributed by Lukas

For many private European biotechs, flat or down valuations have become the new normal as they struggle to raise money despite having quality science,...

Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success

09 May 2023

Contributed by Lukas

This year’s Bio€quity Europe conference aims to define what European biotech’s “playbook for success” should be in the industry’s “new n...

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

09 May 2023

Contributed by Lukas

Acelyrin last week parlayed a late-stage asset for hidradenitis suppurativa and veteran leadership into one of biotech’s largest-ever NASDAQ IPOs. O...

Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal

01 May 2023

Contributed by Lukas

Biopharma companies believe a draft law that seeks to overhaul European pharmaceutical policy for the first time in years is out of sync with innovati...

Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights

25 Apr 2023

Contributed by Lukas

Top-tier European VCs are still attracting capital to deploy, Director of Biopharma Intelligence Stephen Hansen said on the latest BioCentury This Wee...

Ep. 172 - AACR Insights

20 Apr 2023

Contributed by Lukas

BioCentury’s analysis of AACR 2023 abstracts found new targets light on immuno-oncology, said Executive Director Lauren Martz on a special edition o...

Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology

17 Apr 2023

Contributed by Lukas

M&A such as Monday’s proposed takeout of Prometheus by Merck & Co. is one of the few factors that can help reverse the negative sentiment ha...

Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA

10 Apr 2023

Contributed by Lukas

The ruling on abortion drug mifepristone issued Friday by Texas District Judge Matthew Kacsmaryk could destabilize drug regulation, opening up every F...

Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS

03 Apr 2023

Contributed by Lukas

On the latest BioCentury This Week podcast, BioCentury’s editors assess the implications of the FTC’s challenge to the $7.1 billion acquisition of...

Ep. 168 - VCs' Take on SVB & New ALS Endpoint

27 Mar 2023

Contributed by Lukas

On the latest BioCentury This Week podcast, BioCentury’s editors assess responses to their VC survey regarding the collapse of Silicon Valley Bank i...

Ep. 167 - The IRA, T Cell Therapies & The Distillery

21 Mar 2023

Contributed by Lukas

 On the latest BioCentury This Week podcast, BioCentury’s editors assess how companies are upending pipeline and business strategies due to the Inf...

Ep. 166 - SVB Shakeout: Next Steps for Biotech

17 Mar 2023

Contributed by Lukas

On a special edition of the BioCentury This Week podcast, Editor in Chief Simone Fishburn and Director of Biopharma Intelligence Stephen Hansen assess...

Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen

13 Mar 2023

Contributed by Lukas

On the latest BioCentury This Week podcast, BioCentury’s editors assess the fallout from the collapse of SVB and the sale of SVB UK to HSBC. BioCent...

Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

07 Mar 2023

Contributed by Lukas

On the latest episode of the BioCentury This Week podcast, BioCentury’s editors assess the challenges and opportunities facing Christopher Viehbache...

Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure

28 Feb 2023

Contributed by Lukas

Leaked drafts of legislation overhauling Europe’s pharmaceutical laws are causing consternation at biopharma companies. BioCentury’s editors discu...

Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up

21 Feb 2023

Contributed by Lukas

On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the latest payment models from CMS could mean for cell and gene therap...

Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs

13 Feb 2023

Contributed by Lukas

Last week’s Oncologic Drugs Advisory Committee meeting to discuss PD-1 inhibitor Jemperli offered insights into new endpoints, single-arm studies an...

Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs

07 Feb 2023

Contributed by Lukas

Via new guidance and its Project Optimus, FDA is pushing companies to do dose-optimization studies instead of maximum-tolerated dose studies, BioCentu...

Ep. 159 - BIO's Priorities, ESG & Venture Trends

31 Jan 2023

Contributed by Lukas

BIO’s push for FDA to be more flexible on accelerated approval requirements is unlikely to resonate at the agency, Washington Editor Steve Usdin sai...

Ep. 158 - CAR T Manufacturing & Orphan Drugs

24 Jan 2023

Contributed by Lukas

New manufacturing systems for CAR Ts aren’t just about speed, Executive Director for Biopharma Intelligence Lauren Martz said on the latest BioCentu...

Ep. 157 - 2023 Markets Outlook & Buyside Picks

18 Jan 2023

Contributed by Lukas

Investors broadly agree that biotech indexes won’t revisit the lows seen last year, but they’ll need their portfolio companies to survive until th...

Ep. 156 - JPM Highlights & Alzheimer's Takeaways

09 Jan 2023

Contributed by Lukas

A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of th...

Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends

04 Jan 2023

Contributed by Lukas

The U.K. government is signaling that life sciences companies will be shielded from changes to an R&D tax relief policy that would otherwise leave...

Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery

20 Dec 2022

Contributed by Lukas

Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said...

Ep. 153 - The Inflation Reduction Act

19 Dec 2022

Contributed by Lukas

A strategy for navigating the Inflation Reduction Act is essential for every biopharma company, regardless of size or location, Washington Editor Stev...

Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs

13 Dec 2022

Contributed by Lukas

The $28.7 billion takeout of Horizon Therapeutics by Amgen marks a continuation of the large cap biopharma’s return to the inflammatory and autoimmu...

Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum

06 Dec 2022

Contributed by Lukas

CTAD data for lecanemab showed more definitively than any past readout that targeting β-amyloid can lead to clinical benefit for Alzheimer’s patien...

Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices

28 Nov 2022

Contributed by Lukas

A model term sheet created by a consortium of academic institutions, VCs and law firms could reduce the negotiation time around life sciences start-up...

Ep. 149 - Takeaways from the East-West Summit

21 Nov 2022

Contributed by Lukas

There are clear indicators of the maturation of China’s biotech sector, although east and west biopharma leaders have diverging views on how easy cr...

Ep. 148 - East-West Summit Highlights Part 2

18 Nov 2022

Contributed by Lukas

As China’s biopharma companies experience their first “biotech winter,” they should be engaged in active portfolio management, stopping projects...

Ep. 147 - East-West Summit Highlights Part 1

16 Nov 2022

Contributed by Lukas

Cash conversation and sticking to priorities are essential for China’s biotech’s as they navigate today’s gloomy funding environment, Zhaoke Oph...

Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery

15 Nov 2022

Contributed by Lukas

The lack of a “red wave” in the U.S. midterm elections sets up a “last gasp of old-fashioned, horse-trading politics” by lawmakers that could ...

Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK

07 Nov 2022

Contributed by Lukas

 BIO needs to pick a leadership team rather than a leader to give the trade group all the skills it needs moving forward, Washington Editor Steve Usd...